Day: October 21, 2019

LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) — Cinedigm Corp. (NASDAQ:CIDM) today announced a new distribution agreement with leading Chinese entertainment company Starrise Media Holdings Limited (“Starrise Media”) to release films in China theatrically, via broadcast television and to digital platforms.  The two companies have worked together previously on bringing Chinese content to the US.The initial focus of the alliance will be on new premium feature films, with goal of five to ten films distributed into China per year.Starrise is a public company listed on the main board of the Stock Exchange of Hong Kong Limited (stock code: 01616). It mainly invests in film, television and other short form content. Starrise distributes film content theatrically and to all key media platforms in China and is committed to significantly growing...

SHERMAN OAKS, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) — We are advised by Petroteq Energy Inc. that journalists and other readers should disregard the news release, Petroteq Demonstrates Stabilized Production issued October 21, 2019, over GlobeNewswire.

MONTREAL, Oct. 21, 2019 (GLOBE NEWSWIRE) — AM Resources CORP. (“AM”) (TSXV: AMR) is pleased to announce that it has mobilized crews to commence diamond drilling activities on the Rio Negro and Esperanza properties.The program calls for up to 500 m of diamond drilling to be completed on Rio Negro and Esperanza properties. The diamond drill program will commence before the end of October 2019 and is expected to be completed by the end of November 2019. Data from this definition drilling will be used by the Colombian contractor for a better assessment of the Rio Negro and Esperanza properties with a goal to begin a small-scale production in February 2020 (May 7, 2019 press release).The technical and scientific content of this press release has been reviewed and approved by Pierre O’Dowd, P. Geo., the Corporation’s qualified...

Call Scheduled for Thursday, October 24th at 10:30am Eastern TimeLOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) — Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that it will host a Key Opinion Leader (KOL) call on the role of CAP-1002 in the of treatment of Duchenne Muscular Dystrophy (DMD) on Thursday, October 24th at 10:30am Eastern Time.The call will feature a presentation by KOL Craig M. McDonald, MD, UC Davis Health, and principal investigator of Capricor’s HOPE-2 trial who will provide an overview of Duchenne Muscular Dystrophy (DMD), its progression, current treatment options, and new treatments in development for the disease. Dr. McDonald...

NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from the Transpher A Study, the Company’s ongoing Phase 1/2 clinical trial evaluating ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA), and research updates from its library of novel AIMTM adeno-associated virus (AAV) capsids at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 22-25, 2019 in Barcelona, Spain.  The data will be presented as follows:Safety, Tolerability, Biopotency and Neurocognitive Data of ABO-102 in Transpher A, an Open-Label, Multicenter, Single-Dose, Dose-Escalation, Phase 1/2 Clinical Trial in Sanfilippo Syndrome type A (Mucopolysaccharidosis IIIA)Oral Presentation...

MANALAPAN, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) — Sun Pacific Holding Corp. (OTHER OTC: SNPW) announces that its subsidiary, MedRecycler–RI, Inc. (“MedRecycler”), has entered into a profit participation partnership agreement with its medical waste to energy equipment manufacturer. The manufacturer will contribute approximately $3.1 million in Hydrochloric acid (“HCL”) refining equipment that will allow elements of the MedRcycler medical waste residuals to be processed into HCL for sale. The partnership agreement provides for the contribution of the processing equipment in return for a twenty percent (“20%”) gross profit participation right from the processing and sale of the HCL. MedRecycler will contribute and utilize elements of the residual that is produced from the processing of medical waste, along with housing and operating...

MONACO, Oct. 21, 2019 (GLOBE NEWSWIRE) — Navios Maritime Acquisition Corporation (“Navios Acquisition”) (NYSE: NNA), an owner and operator of tanker vessels, announced today the repayment of its Term Loan B on October 18, 2019.Angeliki Frangou, Chairman and Chief Executive Officer of Navios Acquisition stated, “We are pleased with the repayment of the Term Loan B as we devoted a great deal of effort to achieving this result. Through a combination of sale-and-leaseback transactions, commercial bank debt and cash, we extended the maturities of our debt through 2027, reduced our cost of capital and strengthened our balance sheet.”The outstanding balance of the Term Loan B at June 30, 2019 was $196.8 million and was repayable in June 2020. Navios Acquisition funded the repayment as follows:Following the completion of the repayment of...

ALLIANCE TRUST PLC                                  At the close of business on Friday 18 October 2019:The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Par, was–       excluding income, 827.4p–       including income, 832.9p  The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was–       excluding income, 816.3p–       including income, 821.8pFor further information, please contact: –NotesNet Asset Values are calculated in accordance with published accounting policies and AIC guidelines.The fair value of the Company’s fixed loan notes is calculated by reference to a benchmark gilt.

LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (NASDAQ: ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH). West is seeking approval for use as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency.The primary focus of the CRL relates to the FDA determination that certain pharmacodynamic parameters were not adequately achieved.“West and Assertio will work together to determine how best to address the CRL,” said Arthur Higgins, President and CEO of Assertio. “In the meantime, we continue...